We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
Pharma group behind blockbuster drug wants to supersize its market impact
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Danish group has expanded manufacturing capacity but says demand will continue to outstrip supply
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
It follows surge in popularity of Ozempic, which is often used for weight loss
Analysts anticipate that Ozempic and Wegovy will hurt sales at some groups as patients reduce calorie intake
Danish drugmaker behind Wegovy and Ozempic has become Europe’s biggest company
Soaring sales for Novo Nordisk’s products mean market capitalisation now exceeds country’s GDP
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
Danish pharma chief is leading the expansion of blockbuster obesity drug that propelled shares to record high
Shares rise after Danish pharma group launches anti-obesity drug Wegovy in UK
Achievement highlights success of drugmaker on list of companies skewed towards the luxury sector
Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication
A new study bolsters the case that semaglutide is not merely a vanity drug but has a key role to play in treating obesity
Danish pharma group is also benefiting from strong US demand for its diabetes treatment
US bank stocks stumble after Moody’s cut ratings of midsized lenders
Drugs that tackle obesity, diabetes and heart disease are good for profits and the public
Shares in Danish drugmaker and US rival Eli Lilly surge to record highs after positive trial of weight-loss drug
Legal and regulatory actions are more likely to drag on earnings than negate them
Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk
German group aims to join companies whose fortunes have been transformed by weight loss treatments
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
UK Edition
